Skip to Content
Merck
All Photos(1)

Key Documents

EHU070711

Sigma-Aldrich

MISSION® esiRNA

targeting human TINAG

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51
Pricing and availability is not currently available.

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

TGCAAAATGGACCAGTTCAAGCCATAATGCAAGTCCGTGAAGATTTCTTCCATTATAAGACAGGGATATACAGACATGTTACCAGCACAAATAAAGAATCAGAAAAATATCGAAAGCTTCAGACACATGCAGTCAAACTCACTGGATGGGGCACACTGAGAGGAGCACAAGGGCAGAAAGAAAAATTTTGGATTGCTGCCAATTCCTGGGGAAAGTCATGGGGAGAGAATGGCTATTTCAGGATTCTTCGAGGAGTAAATGAGTCCGACATTGAAAAGTTGATTATCGCAGCTTGGGGCCAACTGACGAGTTCTGATGAACCATAACATATCATTAAATTTCCATAAGGTCATGCCTTTAAGTAACCCCCTAAATTGAAGTTTAGCAATATGACATTCTTGGTGACAGTGG

Ensembl | human accession no.

ENSG00000137251

NCBI accession no.

NM_014464

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... TINAG(27283) , TINAG(27283)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
QCS

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Meng-Hui Zhang et al.
Cancer biomarkers : section A of Disease markers, 23(1), 33-43 (2018-07-12)
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy that has a poor prognosis. Through the literatures, TINAG significantly participated in the processes of the renal-associated diseases, but there were no studies about the roles of TINAG in the HCC development.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service